Title: efficacy of intravitreal dexamethasone implant on hard exudate in diabetic macular edema.

Published on Jan 15, 2021in BMC Ophthalmology1.413
· DOI :10.1186/S12886-020-01786-2
Chang Ki Yoon1
Estimated H-index: 1
(Seoul National University Hospital),
Min Sagong15
Estimated H-index: 15
(Yeungnam University)
+ 7 AuthorsHyun Woong Kim14
Estimated H-index: 14
BACKGROUND To investigate the effect of intravitreal dexamethasone implant (DEX implant) on hard exudate (HE) accompanying diabetic macular edema (DME). METHODS This study was a non-comparative non-randomized 1-year prospective interventional study. Patients with DME and HE were treated using DEX implant two or three times. Color fundus photography and optical coherence tomography (OCT) were performed at every visit. HE area was measured semi-automatically from the fundus photographs. RESULTS Thirty-five patients completed the study. Eleven patients (31.4%) received two injections, while the remaining received three times. HE area (primary outcome) significantly decreased from 1.404±2.094 mm2 (baseline) to 0.212±0.592 mm2 (last visit), which was 24% of the baseline HE area (P<0.001). HE1500 (HE within 1500 μm from the fovea) area also decreased significantly from 0.382±0.467 mm2 to 0.066±0.126 mm2 (P<0.001). Furthermore, anaverage best corrected visual acuity (BCVA) improvement of 4.4 Early Treatment Diabetic Retinopathy Study (ETDRS) letters was observed (from 49.9±18.3 to 54.3±20.4 letters) (P= 0.008). Central macular thickness (CMT) decreased from 455.8±23.6 μm to 366.8±31.1 μm (P=0.009). Repetitive measurements for entire study duration was analyzed using generalized estimating equations (GEE), where BCVA was related to age, CMT, and HE1500 area in multivariate analyses. CONCLUSION DEX implant could reduce and suppress HE in DME for one year with two or three injections. And centrally located HE area (HE1500 area) is related to vision. TRIAL REGISTRATION ClinicalTrials.gov, NCT02399657 , Registered 26 March 2015.
#1Sowmya SrinivasH-Index: 10
#2Aditya VermaH-Index: 3
Last. Srinivas R. Sadda (UCLA: University of California, Los Angeles)H-Index: 79
view all 7 authors...
Abstract Purpose To study the effect of monthly 0.3 mg intravitreal ranibizumab injections on intraretinal hard exudates (HEs) and correlate the effect with macular thickness in eyes with diabetic macular edema (DME). Design Randomized control trial Methods Twenty-four eyes of 24 subjects with DME were included in this IRB-approved, prospective longitudinal study. Subjects were randomly assigned to receive monthly intravitreal ranibizumab injections either until macular edema resolved or until b...
3 CitationsSource
#1Susan B. Bressler (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 74
#2Isoken OdiaH-Index: 5
Last. Jennifer K. Sun (Harvard University)H-Index: 39
view all 9 authors...
Importance Identifying the factors that are associated with the magnitude of treatment benefits from anti–vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) may help refine treatment expectations. Objective To identify the baseline factors that are associated with vision and anatomic outcomes when managing DME with anti-VEGF and determine if there are interactions between factors and the agent administered. Design, Setting, and Participants This post hoc anal...
32 CitationsSource
#1Michael SingerH-Index: 16
#2Pravin U. DugelH-Index: 51
Last. John MaltmanH-Index: 3
view all 5 authors...
BACKGROUND AND OBJECTIVE: Dexamethasone intravitreal implant (DEX) (Ozurdex; Allergan plc, Dublin, Ireland) is approved for the treatment of diabetic macular edema (DME). This study assessed the real-world effectiveness, safety, and reinjection interval of DEX in adult patients with DME. PATIENTS AND METHODS: This was a phase 4, prospective, multicenter (18 U.S. sites), observational study. RESULTS: The study population comprised 177 patients (180 eyes; 93.8% previously treated). Baseline mean b...
14 CitationsSource
#1Yong Un Shin (Hanyang University)H-Index: 11
#2Eun Hee Hong (Hanyang University)H-Index: 5
Last. Heeyoon Cho (Hanyang University)H-Index: 9
view all 6 authors...
Background To quantitatively compare short-term hard exudates (HEs) alteration in patients with diabetic macular edema (DME) after intravitreal triamcinolone, dexamethasone implant or bevacizumab injections.
12 CitationsSource
#1Ji Woong Park (DU: Dankook University)H-Index: 1
#2Bong Hui Kang (DU: Dankook University)H-Index: 3
Last. Kyong Jin Cho (DU: Dankook University)H-Index: 8
view all 4 authors...
Background Pupil size is an important factor in predicting post-operative satisfaction. We assessed the correlation between pupil size, measured by Humphrey static perimetry, and various affecting factors in patients with glaucoma.
11 CitationsSource
#1Rishi P. Singh (Cleveland Clinic)H-Index: 22
#2Charles C. Wykoff (Houston Methodist Hospital)H-Index: 41
Last. Quan Dong NguyenH-Index: 58
view all 15 authors...
Purpose To examine the relationship between glycemic control at baseline and response to anti–vascular endothelial growth factor treatment for diabetic macular edema (DME). Design Post hoc analysis of 2 similarly designed phase III trials, VISTA and VIVID. Participants Patients with central-involved DME. Methods Both VISTA and VIVID compared efficacy and safety of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for DME. Current analysis focused on comparison within e...
9 CitationsSource
#1Namritha Patrao (Moorfields Eye Hospital)H-Index: 2
#1Namritha Patrao (Moorfields Eye Hospital)H-Index: 6
Last. Ranjan Rajendram (UCL: University College London)H-Index: 12
view all 8 authors...
Purpose To determine visual acuity (VA) and spectral-domain optical coherence tomography (OCT) outcomes with intravitreal ranibizumab for diabetic macular edema (DME) in a United Kingdom National Health Service clinical setting. Design Retrospective interventional case series. Participants Consecutive patients with DME, treated with the first ranibizumab injection between August 2013 and March 2014 across 4 sites of Moorfields Eye Hospital, London. Methods Two hundred eyes of 164 consecutive pat...
45 CitationsSource
Abstract To compare the visualization of microaneurysms (MA) and the foveal avascular zone (FAZ) area using optical coherence tomography angiography (OCTA) versus fluorescein angiography (FA) in patients with diabetic macular edema (DME). Patients were prospectively recruited for same-day imaging on spectral-domain OCTA and FA. OCTA images were automatically segmented into superficial (sOCTA) and deep (dOCTA) capillary plexuses. The number of visible MAs and the FAZ area were compared between th...
12 CitationsSource
#1Jeffrey S. HeierH-Index: 57
#2Jean-François Korobelnik (French Institute of Health and Medical Research)H-Index: 39
Last. Frank G. Holz (University of Bonn)H-Index: 88
view all 21 authors...
Purpose To compare efficacy and safety of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for diabetic macular edema (DME) over 3 years. Design Two similarly designed phase 3 trials: VISTA DME and VIVID DME . Participants Patients (eyes; n = 872) with central-involved DME. Methods Eyes received IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or laser control. From week 24, if rescue treatment criteria were met, IAI patients received ...
147 CitationsSource
#1Samaneh Davoudi (UMMC: University of Mississippi Medical Center)H-Index: 9
Last. Lucia SobrinH-Index: 33
view all 13 authors...
Supported by the American Diabetes Association Clinical Translational Research Award 1-11-CT-51, Alexandria, VA; NEI K12-EY16335, Bethesda, MD; Research to Prevent Blindness Career Development Award and William & Mary Greve Special Scholar Award, New York City, NY; Harvard Catalyst vertical bar The Harvard Clinical and Translations Science Center Faculty Fellowship, Boston, MA; Massachusetts Lions Eye Research Fund, Abington, MA; Eleanor and Miles Shore Fellowship, Boston, MA; Sara Elizabeth O'B...
13 CitationsSource
Cited By1
#1Ahmet Altun (BAU: Bahçeşehir University)H-Index: 1
#2A. M. Hacimustafaoglu (Medical Park)
Aim. To investigate the change in subfoveal choroidal thickness (SFCT) in vitrectomized eyes with intravitreal dexamethasone (IVD) implant injection for the treatment of diabetic macular edema (DME). Method. In this prospective and controlled study, the vitrectomized eyes of diabetic patients were included. The study group (Group 1) was formed by diabetic vitrectomized eyes with DME. The control group (Group 2) was formed by diabetic vitrectomized eyes without DME. Only one intravitreal IVD impl...